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ab
stract
PURPOSE To compare cisplatin plus fluorouracil (FU) versus carboplatin plus paclitaxel in chemotherapy-naı̈ve
advanced anal cancer to establish the optimal regimen.
PATIENTS AND METHODS Patients who had not received systemic therapy for advanced anal cancer were randomly
assigned 1:1 to intravenous cisplatin 60 mg/m2 (day 1) plus FU 1,000 mg/m2 (days 1-4) every 21 days or carboplatin
(area under the curve, 5; day 1) plus paclitaxel 80mg/m2 (days 1, 8, and 15) every 28 days for 24 weeks, until disease
progression, intolerable toxicity, or withdrawal of consent. Primary end point was objective response rate (ORR).
Primary and secondary end points were assessed in a hierarchicmodel to compare the regimens and pick the winner.
RESULTS We conducted an international multicenter randomized phase II study in 60 centers between De-
cember 2013 and November 2017. Median follow-up was 28.6 months. A total of 91 patients were randomly
assigned: 46 to cisplatin plus FU and 45 to carboplatin plus paclitaxel. ORRwas 57% (95%CI, 39.4% to 73.7%)
for cisplatin plus FU versus 59% (95%CI, 42.1% to 74.4%) for carboplatin plus paclitaxel. More serious adverse
events were noted in the cisplatin plus FU arm (62%) compared with the carboplatin plus paclitaxel arm (36%;
P 5 .016). Median progression-free survival was 5.7 months (95% CI, 3.3 to 9.0 months) for cisplatin plus FU
compared with 8.1 months (95% CI, 6.6 to 8.8 months) for carboplatin plus paclitaxel. Median overall survival
was 12.3 months for cisplatin plus FU (95% CI, 9.2 to 17.7 months) compared with 20 months (95% CI,
12.7 months to not reached) for carboplatin plus paclitaxel (hazard ratio, 2.00; 95% CI, 1.15 to 3.47; P5 .014).
CONCLUSION This is the first international randomized trial to our knowledge conducted in chemotherapy-naı̈ve
advanced anal cancer. Although there was no difference in ORR, the association with clinically relevant reduced
toxicity and a trend toward longer survival suggest that carboplatin plus paclitaxel should be considered as a new
standard of care.
J Clin Oncol 38. © 2020 by American Society of Clinical Oncology
INTRODUCTION
Anal cancer is rare and accounts for , 3% of all GI
malignancies.1 However, incidence has risen over the
past decades. The number of new cases in the United
States was reported as 1.9 per 100,000 men and
women between 2012 and 2016.2,3 A majority of pa-
tients present with localized or locally advanced disease,
where radical chemoradiotherapy (with concurrent mi-
tomycin C with fluorouracil [FU] or capecitabine) is the
standard of care administered with curative intent.4-9
Local failure rates after chemoradiotherapy approach
30%, and for some, salvage surgery is feasible.5,7,10
Metastatic dissemination occurs in 10% of patients
after chemoradiotherapy, whereas , 10% present
with metastatic disease de novo.4,5,7 For those patients
with inoperable or metastatic disease, prognosis re-
mains poor, with relative 5-year survival rates of ap-
proximately 30%.4 Palliative chemotherapy is routinely
offered to these patients.11 To date, no randomized
clinical trial has been conducted in this setting to
inform the optimal chemotherapy regimen. In-
ternational guidelines suggest a platinum agent
combined with fluoropyrimidine for the first-line
treatment of advanced anal cancer12,13 on the basis
of limited evidence from single-arm phase II studies;
response rates of between 34% and 75% and median
overall survival (OS) ranging from 12 to 34 months
have been reported in retrospective studies and single-
arm phase II trials.14-16 Although these data are limited,
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was first reported as treatment for advanced anal cancer in
2011 and was recently combined with carboplatin in
a retrospective series.16-18 Response rates of 69% and
median survival of 12 months have been reported.17 This
observed efficacy has led to some clinicians employing
carboplatin and paclitaxel as first-line treatment for ad-
vanced anal cancer.
The International Rare Cancers Initiative Anal Cancer
Working Group recognized the evidence gap in clinical
decision making for patients with advanced anal cancer as
an area of unmet clinical need, prompting this global
clinical trial comparing cisplatin plus FU versus carboplatin
plus paclitaxel to set a standard of care and establish the
cytotoxic backbone for future clinical trials.
PATIENTS AND METHODS
Study Design and Participants
InterAAct (ClinicalTrials.gov identifier: NCT02051868) was
an international open-label multicenter randomized phase
II trial that recruited patients from 60 centers from the
United Kingdom, Australia, Norway, and the United States.
Eligible patients were age $ 18 years with histologic
confirmation of epidermoid anal squamous carcinoma,
locally recurrent inoperable or metastatic disease, Eastern
Cooperative Oncology Group (ECOG) performance status
(PS) of 0 to 2, andmeasurable disease according to RECIST
(version 1.1). HIV-positive patients were included provided
they were receiving highly active antiretroviral therapy and
CD4 count was $ 200/mL or CD4 count was # 200/mL (ie,
undetectable plasma HIV-positive viral load). Previous
definitive chemoradiotherapy was permitted provided
progression occurred $ 6 months, but no previous sys-
temic treatment for advanced disease was permitted. Pa-
tients were required to have adequate organ function and
adequate cardiac and respiratory function. Exclusion cri-
teria included resectable recurrent localized disease, brain
metastases, and major surgery # 28 days, or palliative
radiotherapy completed # 7 days.
The trial was approved by the National Research Ethics
Committee London Riverside (13/LO/1463), the Medicines
and Healthcare Products Regulatory Agency, and the in-
stitutional review boards of all centers. In the United States,
the study was approved by the National Cancer Institute
Cancer Therapy Evaluation Program via ECOG (EA2133).
Random Assignment
Patients were randomly allocated at a 1:1 ratio to receive
either cisplatin plus FU or carboplatin plus paclitaxel.
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FIG 1. CONSORT diagram. FU,
fluorouracil.
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unit at the Institute for Cancer Research Trials Centre using
a minimization algorithm.19,20 Stratification was by ECOG
PS (0-1 v 2), disease status (locally advanced vmetastatic),
HIV status (positive v negative), and region (United King-
dom v Australia v Europe v United States). Sites were in-
formed electronically of treatment allocation after random
assignment.
Study Procedures
Patients received either intravenous cisplatin (60 mg/m2;
day 1) and FU (1,000 mg/m2; days 1-4) every 21 days or
carboplatin (area under the curve, 5; day 1) and paclitaxel
(80 mg/m2; days 1, 8, and 15) every 28 days. All patients
were treated for 24 weeks or until disease progression,
intolerable toxicity, or withdrawal of consent.
Adverse events (AEs) were evaluated according to the
National Cancer Institute Common Terminology Criteria for
Adverse Events (version 4.0), from random assignment to
30 days after administration of the last study treatment.
Serious AEs (SAEs) were reported from informed consent
up to 30 days after the last study treatment or after, if
deemed related to trial treatment.
Response to treatment was assessed by each investigator
site as per RECIST (version 1.1) criteria using computed
tomography or magnetic resonance imaging scans ob-
tained pretreatment and at 12 weeks, at 24 weeks, and
every 12 weeks thereafter until disease progression. No
central review was undertaken to confirm radiographic
response. Quality of life (QOL) was evaluated before
treatment and then at 7, 12, 24, and 48 weeks using the
European Organisation for Research and Treatment of
Cancer Quality of Life Core 30 Questionnaire and EuroQol
ED-5D5L.
The exploratory translational substudy collecting blood and
tissue was optional. Archival diagnostic tumor biopsies
were retrieved, and optional tumor biopsies on progression
were collected upon further consent.
A research sample of 35 mL of whole blood was collected
from patients pretreatment, at 12 weeks, and at disease
progression. Plasma was isolated from blood samples that
were collected pre- and posttreatment (at 12 weeks) fol-
lowing standard protocols for cell-free DNA isolation. Cir-
culating human papillomavirus (HPV) DNA was measured
in plasma using an amplicon-based next-generation se-
quencing panel interrogating for 8 high-risk HPV subtypes
(16, 18, 31, 33, 35, 45, 52, and 58). To classify HPV-
positive and -negative samples using the NGS panel, we set
a threshold whereby a sample was classified positive if
there were 3 reads present from . 10 different HPV
amplicons for each HPV subtype.
Outcomes
The primary end point was best overall response rate
(ORR), defined as the percentage of patients achieving
confirmed partial (PR) or complete response (CR) as per
RECIST (version 1.1). Secondary end points included the
feasibility of international setup and recruitment;
progression-free survival (PFS; time from random assign-
ment to the date of confirmed clinical/radiologic progres-
sion or death resulting from any cause); OS (time from start
of treatment to death resulting from any cause); disease
control rate at 12 and 24 weeks posttreatment, defined as
CR, PR, or stable disease; and assessments of AEs and
QOL. Exploratory objectives included evaluation of circu-
lating HPV DNA in pre- and posttreatment plasma samples
and correlation with radiographic response.








No. % No. %
Sex
Female 32 71 29 63
Male 13 29 17 37
Age, years
Median (range) 61 (40-75) 61 (43-75)
Mean (SD) 60 (9.5) 60 (7.9)
Extent of disease at study entry
Locally advanced 5 11 6 13
Metastatic 40 89 40 87
ECOG PS
0-1 42 93 43 93
2 3 7 3 7
HIV
Negative 43 96 43 93
Positive 2 4 3 7
Induction treatmenta
Chemotherapy 0 0 3 9
Surgery 2 7 1 3
CRT 26 96 33 100
Treatment of LA/metastases
Any 9 20 14 30
Surgery 6 13 8 17
Radiotherapy 3 7 9 20
No. of metastatic sites
0 0 0 1 2
1 9 20 13 28
2 24 53 19 41
3 12 27 10 22
4 0 0 3 6
Abbreviations: CRT, chemoradiotherapy; ECOG PS, Eastern Cooperative
Oncology Group performance status; FU, fluorouracil; LA, locally advanced.
aOf those MO at diagnosis.
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Statistical Analysis
On the basis of an ORR estimate of 40% in the cisplatin plus
FU arm, a clinically relevant difference in ORR between
groups was defined as 10%. Using the selection trial pick-
the-winner design for phase II randomized trials,21 the trial
was originally designed to require 40 patients (accounting
for 10% dropout rate) to be recruited to each arm (total, 80)
to detect a 10% difference in ORR between the arms with
80% power.
Because approximately 17% of patients were initially
nonassessable for the primary end point, the study sample
size was increased up to a maximum of 90 patients to allow
36 assessable patients per arm. On the basis of the se-
lection trial design, primary and secondary study end points
were assessed in a hierarchic model to compare the 2
regimens and pick the winner. According to this model, the
regimen with the higher ORR would be declared the
winner. If there were no difference in ORR, the regimen with
the lower rate of grade 3 to 4 toxicities or AEs would be
selected. If there were no difference in either ORR or
toxicities, the regimen with superior QOL data would be
chosen. If no winner were picked after assessing activity,
toxicity, and QOL, a strong recommendation on which
regimen should be used could not be made.
The primary analysis of best response was based on the
modified intention-to-treat (ITT) population, defined as all
patients randomly assigned in the study who were eligible,
received at least 1 cycle of chemotherapy, were assessable
for response, or had evidence of clinical progression. AEs
were assessed in the safety population, consisting of all
patients who had received at least 1 cycle of randomly
assigned treatment.
ORR was reported by arm with 95% CIs and compared
between arms using a x2 test. In addition, a logistic re-
gression model was fitted to adjust for the stratification
variables and calculate an odds ratio (with associated
95% CI) between arms. Kaplan-Meier curves were plotted
for PFS and OS; treatment effect hazard ratios (HRs; with
95%CIs and P values) were obtained from Cox proportional
hazards regression models, which included HRs adjusted
for random assignment stratification factors.
AEs were reported as the worst grade per patient per event,
and comparison between groups by a test of proportions
was calculated with x2 or Fisher’s test. QOL scores and
differences from baseline over time by treatment were
tabulated. Only variations of $ 10 points compared with
baseline were considered clinically significant.22
RESULTS
A total of 91 patients were recruited to the study between
December 2013 and November 2017 from 31 centers; 45
were randomly assigned to carboplatin plus paclitaxel and
46 to cisplatin plus FU (Fig 1).
Patient demographics were well balanced between both
treatment arms at baseline (Table 1). A majority of patients
had metastatic disease, had ECOG PS of 0 to 1, and were
HIV negative. Of those who had previously received
treatment for localized disease, a majority had received
chemoradiotherapy.
Of the randomly assigned patients, 42 in each arm received
study treatment (Fig 1). The modified ITT population
comprised 39 patients in the carboplatin plus paclitaxel
arm and 35 in the cisplatin plus FU arm. The safety
population consisted of 42 patients in each cohort.
Recruitment took longer than expected initially; however,
in the last 24 months of recruitment, the target of 25 to 30
patients per year was achieved. Examining recruitment
feasibility, 31 (52%) of 60 open centers recruited at least
1 patient. The regional distribution of patient recruitment
for the 91 patients was as follows: United Kingdom (n 5
68), Europe (n 5 8), North America (n 5 12), and
Australia (n 5 3).
Median number of cycles provided was 4.5 in the cisplatin
plus FU arm versus 6 in the carboplatin plus paclitaxel arm;
47% received the planned 24 weeks versus 30%, re-
spectively. Dose delays occurred in 64% versus 76% of
patients and dose reductions were required in 67% versus








No. % No. %
CR 5 12.8 6 17.1
PR 18 46.2 14 40
SD 10 25.6 7 20.0
PD 6 15.4 8 22.9
CR/PR 23 59 20 57.1
95% CI 42.1 to 74.4 39.4 to 73.7
Abbreviations: CR, complete response; FU, fluorouracil; PD, progressive disease;































FIG 2. Waterfall plot of objective response. FU, fluorouracil.
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69% of patients in the cisplatin plus FU arm versus car-
boplatin plus paclitaxel arm, respectively. Mean dose-
intensity (6 standard deviation) was similar for both
arms—cisplatin plus FU arm: cisplatin, 80.4% (6 17.4%)
and FU, 80.8% (6 23.4%); carboplatin plus paclitaxel arm:
carboplatin, 82% (6 13.5%) and paclitaxel, 83.7% (6
19.4%).
As of May 2019, median follow-up for all patients was 28.6
months. ORR was 57% (95% CI, 39.4% to 73.7%; CR,
17%; PR, 40%) for cisplatin plus FU versus 59% (95% CI,
42.1% to 74.4%; CR, 12.8%; PR, 46.2%) for carboplatin
plus paclitaxel (Table 2; Fig 2). CR was observed regardless
of disease burden or stage. At the time of analysis, 8 pa-
tients (22.9%) in the cisplatin plus FU arm had experi-
enced disease progression compared with 6 (15.4%) in the
carboplatin plus paclitaxel arm.
Median PFS was 5.7 months (95% CI, 3.3 to 9.0 months)
for cisplatin plus FU compared with 8.1 months (95% CI,
6.6 to 8.8 months) for carboplatin plus paclitaxel and was
not statistically significant (Fig 3). The unadjusted HR was
1.27 (95% CI, 0.75 to 2.14; P 5 .375). After adjusting for
PS, HIV status, disease status, and region, the adjusted HR
was 1.17 (95% CI, 0.68 to 2.02; P 5 .564).
There was a trend toward a significant difference in OS
favoring the carboplatin plus paclitaxel arm (Fig 4). Median
OS was 12.3 months for cisplatin plus FU (95% CI, 9.2 to
17.7] compared with 20 months (95% CI, 12.7 months to
not reached) for carboplatin plus paclitaxel, with an un-
adjusted HR of 2.00 (95% CI, 1.15 to 3.47; P5 .014). After
adjusting for stratification factors, the adjusted HRwas 1.78
(95% CI, 0.98 to 3.23; P 5 .059).
The AE profile is summarized in Table 3. There was more
neutropenia and anemia with carboplatin plus paclitaxel
but more nausea, vomiting, mucositis, and diarrhea with
cisplatin plus FU. There were no grade 5 toxicities. Overall,
there were more SAEs with cisplatin plus FU versus car-
boplatin plus paclitaxel (62% v 36%; P 5 .016).
QOL assessment was limited because of poor compliance
with return of the questionnaires. Aminimal number of QOL
questionnaires were returned after 12 weeks, limiting
analysis. At baseline, 76% versus 67% of questionnaires
were completed, reducing at 12 weeks to 46% versus 49%,
for the cisplatin plus FU and carboplatin plus paclitaxel
arms, respectively. Global health status score seemed to
worsen (not significantly) for the cisplatin plus FU arm at
24 weeks but remained unchanged for carboplatin plus
paclitaxel; however, data are limited because of small
numbers.
Three patients in each cohort underwent surgery (meta-
sesectomy, n 5 2; palliative surgery, n 5 1) and thus were
balanced. After completion of treatment, 25 patients (54%)
received subsequent anticancer therapy in the cisplatin
plus FU cohort versus 17 (38%) in the carboplatin plus
paclitaxel cohort, although overall, there were no statistical
differences (Table 4), with crossover from each arm on
progression. There were also no differences between co-
horts in poststudy radiotherapy.
Exploratory Correlatives
Of 91 patients, 35 (39%) had baseline HPV blood results
and tissue P16 results available. Of 31 patients with p16-
positive tumor tissue, 30 were positive for HPV DNA. For
those 4 patients with p16-negative tumor tissue, 3 were
negative by HPV DNA (sensitivity, 97%; specificity, 75%;
Appendix Table A1, online only). There were 28 patients
with blood samples collected at baseline, during treatment
(12 weeks), or on progression. Of these, 5 patients con-
verted from positive HPV DNA pretreatment to negative
posttreatment by virtue of a reduction in HPV DNA below
the threshold value of 3. For these 5 patients (CR, n 5 2;
PR, n 5 3), median duration of response was 46 weeks
(range, 38-64 weeks), with 1 still responding at last follow-
up. All patients with radiologic progression had HPV DNA
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FIG 4. Kaplan-Meier analysis of overall survival (OS). FU,
fluorouracil.
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DISCUSSION
InterAACT was the first international prospective random-
ized trial to our knowledge in advanced anal cancer. Al-
though there was no difference in ORRs, carboplatin plus
paclitaxel was associated with significantly fewer SAEs
(36% v 62%) and fewer clinically relevant AEs, including
mucositis, fatigue, and thromboembolism, and a trend
toward longer OS that could be clinically meaningful.
Furthermore carboplatin plus paclitaxel does not require
prolonged infusion, unlike cisplatin plus FU. Therefore, as
per the trial design, carboplatin plus paclitaxel was selected
for future investigation.
Of note, more patients (n5 25; 54%) received subsequent
systemic anticancer therapy in the cisplatin plus FU arm
than in the carboplatin plus paclitaxel arm (n 5 17; 38%).
Furthermore, there were no clear differences in choice of
subsequent systemic treatment or in lines of therapy ad-
ministered between the 2 arms. This was similar regardless
of subsequent radiotherapy, surgery, and radiofrequency
ablation.
As per the trial design, survival was a secondary end point
and exploratory and therefore should be interpreted with
caution. Additionally, the number of events for OS was
small, with broad CIs. Nevertheless, the efficacy data for the
cisplatin plus FU arm are in keeping with previous historical
reported series,14,23,24 whereas historical data for carbo-
platin and paclitaxel in this setting are limited.
Despite our ability to conduct and complete this trial
successfully, it had its limitations. One primary limitation of
InterAACT was the small randomized phase II design, al-
though this is considered a rare cancer, with no previous
reported randomized trials. It is noteworthy that a potentially
meaningful difference in OS favoring carboplatin plus
paclitaxel was reported, with no apparent difference in
response rate or PFS. One explanation for this is that there
was no independent central radiologic review of imaging in
this open-label trial, which could have led to assessment
bias. Additionally, although subsequent lines and types of
systemic therapy were well balanced, the sequence of
therapy may have differed and may have influenced OS.
Finally, it is plausible that paclitaxel causes immunogenic
modulation of tumor cells and microenvironment, causing
increased sensitivity to antigen-specific cytotoxic T-cell
killing. This has been demonstrated in preclinical studies
and could account for the prolonged survival.25 This may
provide a sound rationale for a combination approach of
systemic chemotherapy with immunotherapy.
Furthermore, compliance with QOL questionnaires led to
difficulties in interpretation of the QOL data. Our exploratory
correlative analysis was also limited by sample size. Nev-
ertheless, there was high sensitivity for HPV DNA detection
at baseline when comparing with tumor tissue. The re-
duction of HPV DNA below the threshold level in some
patients who demonstrated radiologic response is intriguing
but needs further validation in a larger series.
TABLE 3. Selected Grade $ 3 AEs






Difference 95%CINo. % No. %
Anemia 4 10 2 5 5 26 to 16
Thrombocytopenia 0 0 2 5 25 211 to 2
Neutropenia 12 29 8 19 9.5 29 to 28
Diarrhea 1 2 2 5 22 210 to 6
Fatigue 4 10 8 19 210 224 to 5
Febrile neutropenia 2 5 4 10 25 216 to 6
Infection 5 12 6 14 22 217 to 12
Mucositis 0 0 11 26a 226 239 to 213
Nausea 1 2 7 17 214 226 to 22
Vomiting 2 5 5 12 27 219 to 5
Neuropathy 1 2 0 0 2 22 to 7
Thromboembolism 1 2 5 12 29 220 to 1
Arrythmias 0 0 2 5 25 211 to 2
Hearing impairment 0 0 1 2 22 27 to 2
Overall 30 71 32 76 25 224 to 14
SAEs 15 36 26 62a 226 247 to 25
Abbreviations: AE, adverse event; FU, fluorouracil; SAE, serious adverse event.
aStatistically significant (exact test).
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Since the initiation of InterAACT, Kim et al26 have reported
a single-arm multicenter study of docetaxel, cisplatin, and
FU in patients with treatment-naı̈ve metastatic anal cancer.
The investigators observed an encouraging response rate of
83% and PFS of 11 months. However, 46 patients (70%)
developed at least 1 grade 3 to 4 AE. Therefore, this reg-
imen should be provided with caution and only be con-
sidered in patients with close follow-up and excellent PS.
Although conducting clinical trials in rare cancers can be
challenging, our collaborative effort for the InterAACT trial
proved successful. Initially, recruitment was slower than
anticipated; however, we eventually successfully demon-
strated the feasibility of international collaboration across
multiple countries for a rare cancer and achieved target
recruitment once all centers were activated. Furthermore,
we now have an established international anal cancer
network for future collaborative studies. After our
presentation of the data at the European Society for Medical
Oncology (ESMO) meeting, a revision to the 2019 National
Comprehensive Cancer Network and ESMO guidelines now
list carboplatin and paclitaxel as the preferred treatment
option for patients with treatment-naı̈ve metastatic anal
cancer.
In summary, InterAACT, an international randomized
phase II trial in the first-line setting of advanced anal
cancer, demonstrated no difference in objective response
between cisplatin plus FU versus carboplatin plus pac-
litaxel. However, carboplatin plus paclitaxel was associ-
ated with a more favorable toxicity profile and significant
trend toward prolonged OS. These data support the
consideration of carboplatin plus paclitaxel as a new
standard of care in untreated advanced anal cancer and
a cytotoxic platform for the development of future phase III
trials.
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APPENDIX
TABLE A1. Correlation of Circulating HPV and Tissue p16 Analysis
p16 Result
HPV Baseline Blood Result
TotalNegative Positive
Negative 3 1 4
Positive 1 30 31
Total 4 31 35
NOTE. Sensitivity, 97%; specificity, 75%.
Abbreviation: HPV, human papillomavirus.
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